References
- Berger T, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003; 349(2)139–145
- McFarland HF. The B cell—old player, new position on the team. N Engl J Med 2008; 358(7)664–665
- Ponomarenko NA, et al. Catalytic activity of autoantibodies toward myelin basic protein correlates with the scores on the multiple sclerosis expanded disability status scale. Immunol Lett 2006; 103(1)45–50
- Ponomarenko NA, et al. Autoantibodies to myelin basic protein catalyze site-specific degradation of their antigen. Proc Natl Acad Sci USA 2006; 103(2)281–286
- Belogurov AA, Jr, et al. Recognition and degradation of myelin basic protein peptides by serum autoantibodies: Novel biomarker for multiple sclerosis. J Immunol 2008; 180(2)1258–1267
- Lorentzen JC, et al. Protracted, relapsing and demyelinating experimental autoimmune encephalomyelitis in DA rats immunized with syngeneic spinal cord and incomplete Freund's adjuvant. J Neuroimmunol 1995; 63(2)193–205
- Teitelbaum D, et al. Oral glatiramer acetate in experimental autoimmune encephalomyelitis: Clinical and immunological studies. Ann NY Acad Sci 2004; 1029: 239–249
- Filippi M, et al. Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: A multicentre, double-blind, randomised, placebo-controlled study. Lancet Neurol 2006; 5(3)213–220
- Xu LY, et al. Suppression of ongoing experimental allergic encephalomyelitis (EAE) in Lewis rats: Synergistic effects of myelin basic protein (MBP) peptide 68–86 and IL-4. Clin Exp Immunol 2000; 120(3)526–531